Table 4.

Patients’ survival rates according to pN and MR-LLN status

Groups	Overall survival (%)
	1 year	2 years	3 years	4 years	5 years
pN0, no LLN visible	100.0%	99.0%	98.4%	96.6%	95.3%
pN0, SA < 8 mm	100.0%	96.6%	94.1%	89.6%	85.4%
pN0, SA ≥ 8 mm	100.0%	61.5%	53.8%	53.8%	40.4%
pN1, no LLN visible	96.5%	84.8%	80.1%	77.5%	75.9%
pN2, no LLN visible	91.3%	77.8%	65.1%	61.4%	55.1%

Groups	Metastatic-free survival (%)
	1 year	2 years	3 years	4 years	5 years
pN0, no LLN visible	98.7%	96.4%	95.4%	94.3%	94.3%
pN0, SA < 8 mm	95.6%	88.6%	88.6%	88.6%	88.6%
pN0, SA ≥ 8 mm	84.0%	58.8%	58.8%	58.8%	58.8%
pN1, no LLN visible	94.1%	85.4%	84.1%	84.1%	84.1%
pN2, no LLN visible	80.0%	70.4%	67.7%	67.7%	67.7%